

Appendix 5 Subgroup analysis based on the type of digestive system cancers

Incretin	0.20 (0.01,4.93)	1.14 (0.18,7.23)	2.01(0.04,101.27)	0.35 (0.03,4.25)	1.00 (0.61,1.64)
0.19 (0.01,3.15)	Met	NA	NA	2.00 (0.08,49.20)	NA
1.14(0.18,7.24)	6.08 (0.21,177.76)	SU	NA	NA	NA
7.66 (0.34,174.28)	40.97 (0.61,2761.38)	6.74 (0.18,254.22)	SGLT2	NA	0.08 (0.00,2.05)
0.35 (0.03,4.22)	1.88(0.11,31.64)	0.31 (0.01,6.85)	0.05 (0.00,2.48)	TZD	NA
0.99 (0.60,1.64)	5.31 (0.30,93.38)	0.87 (0.13,5.93)	0.13 (0.01,2.89)	2.83 (0.22,35.68)	Placebo

Appendix 5-Figure 1 Odds ratio with 95%CI of subgroup analysis for gastric cancer

Incretin	0.99 (0.10,9.55)	0.92 (0.09,9.66)	2.00(0.04,101.13)	1.05 (0.46,2.38)	0.50 (0.02,16.21)	0.79 (0.59,1.05)
0.99 (0.10,9.56)	Insulin	NA	NA	NA	NA	NA
0.89 (0.09,8.76)	0.90 (0.04,22.48)	Met	NA	NA	NA	NA
3.76 (0.17,84.23)	3.79 (0.08,178.01)	4.23(0.09,200.61)	SGLT2	NA	NA	0.17(0.01,4.13)
1.05 (0.47,2.38)	1.06 (0.10,11.84)	1.19 (0.10,13.44)	0.28 (0.01,6.98)	SU	NA	0.50 (0.01,23.46)
0.50 (0.05,4.79)	0.50 (0.02,12.38)	0.56 (0.02,13.98)	0.13 (0.00,6.20)	0.47 (0.04,5.24)	TZD	NA
0.79 (0.59,1.05)	0.80 (0.08,7.84)	0.89 (0.09,8.90)	0.21 (0.01,4.68)	0.75 (0.32,1.77)	1.59 (0.16,15.66)	Placebo

Appendix 5-Figure 2 Odds ratio with 95%CI of subgroup analysis for colon cancer

Incretin	0.18 (0.02,1.61)	1.12 (0.34,3.72)	3.07 (0.12,75.60)	2.97 (0.12,73.34)	0.75 (0.45,1.26)
0.18 (0.02,1.60)	Insulin	NA	NA	NA	NA
1.15 (0.14,3.80)	6.56 (0.54,80.48)	SU	NA	NA	0.41 (0.03,6.55)
2.69 (0.12,60.10)	15.31 (0.34,690.44)	2.33 (0.08,64.80)	TZD	NA	0.42 (0.01,21.16)
2.98(0.12,73.72)	16.97 (0.35,831.56)	2.58 (0.08,79.08)	1.11 (0.01,96.25)	AGIs	NA
0.75 (0.45,1.25)	4.27 (0.44,41.07)	0.65 (0.18,2.34)	0.28 (0.01,6.36)	0.25 (0.01,6.47)	Placebo

Appendix 5-Figure 3 Odds ratio with 95%CI of subgroup analysis for rectal cancer

Incretin	2.98 (0.12,73.73)	0.60 (0.01,30.31)	0.88 (0.21,3.67)	0.13 (0.01,3.27)	1.05 (0.58,1.92)
3.00 (0.12,74.13)	Insulin	NA	NA	NA	NA
0.60 (0.01,30.29)	0.20 (0.00,31.70)	Met	NA	NA	0.22 (0.01,3.27)
0.91 (0.22,3.78)	0.30 (0.01,10.14)	1.52 (0.02,98.66)	SU	NA	0.50 (0.01,25.46)
0.13 (0.01,3.25)	0.04 (0.00,4.09)	0.22 (0.01,5.43)	0.14 (0.00,4.83)	TZD	NA
1.05 (0.58,1.91)	0.35 (0.01,9.13)	1.75 (0.03,92.62)	1.15 (0.25,5.33)	7.97 (0.31,207.78)	Placebo

Appendix 5-Figure 4 Odds ratio with 95%CI of subgroup analysis for hepatic cancer

Incretin	1.51 (0.32,7.05)	0.23 (0.02,2.24)	1.87 (0.52,6.67)	0.34 (0.01,8.40)	0.85 (0.53,1.36)
1.51 (0.32,7.05)	Insulin	NA	NA	NA	NA
0.23 (0.02,2.22)	0.15 (0.01,2.36)	Met	NA	NA	NA
1.87 (0.52,6.69)	1.24 (0.17,9.12)	8.13(0.60,109.55)	SU	NA	NA
0.48 (0.04,6.10)	0.32 (0.02,6.19)	2.08 (0.07,62.89)	0.26 (0.01,4.41)	TZD	1.25 (0.05,30.96)
0.84 (0.53,1.36)	0.56 (0.11,2.80)	3.67 (0.36,37.25)	0.45 (0.12,1.76)	1.77 (0.14,22.55)	Placebo

Appendix 5-Figure 5 Odds ratio with 95%CI of subgroup analysis for pancreatic cancer